Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction
Joint Authors
Kapłon-Cieślicka, Agnieszka
Budnik, Monika
Filipiak, Krzysztof J.
Opolski, Grzegorz
Tymińska, Agata
Ozierański, Krzysztof
Wancerz, Anna
Sypień, Piotr
Peller, Michał
Balsam, Paweł
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-12, 12 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-10-10
Country of Publication
Egypt
No. of Pages
12
Main Subjects
Abstract EN
Purpose.
To investigate the association of galectin-3 (Gal-3) and soluble ST2 (sST2) and their follow-up changes with the development of heart failure (HF) and echocardiographic parameters of HF (ejection fraction, atrial and ventricular size, left ventricular hypertrophy, e′, and E/e′) in patients with ST-segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (pPCI).
Methods.
A prospective, observational study, BIOSTRAT (Biomarkers for Risk Stratification After STEMI), enrolled 117 patients between October 2014 and April 2017.
Gal-3 and sST2 serum collection and echocardiography were performed twice (during index hospitalization and on a control visit at one-year follow-up).
The primary endpoint was HF onset at one-year follow-up.
Secondary assessments included associations of biomarker concentration with echocardiographic indices of systolic and diastolic dysfunction at baseline and at one year.
Results.
Mean baseline concentrations of Gal-3 and sST2 (7.5 and 26.4 ng/mL, respectively) were significantly increased at one-year follow-up (8.5 ng/mL and p<0.001 and 31.4 ng/mL and p=0.001, respectively).
Patients who reached the primary endpoint (50 patients (48%)) had significantly higher baseline concentrations of both biomarkers and a higher Gal-3 level at one year compared to patients who did not.
Both Gal-3 and sST2 were predictors of the primary endpoint in univariate logistic regression analysis, but only Gal-3 remained significant in multivariate analysis.
There was no clear association between both biomarkers and echocardiographic parameters.
Conclusions.
Baseline, but not one-year, changes of Gal-3 and sST2 concentrations may be useful for risk stratification after STEMI.
However, only Gal-3 was the independent predictor of HF development at one-year observation.
This trial is registered with NCT03735719.
American Psychological Association (APA)
Tymińska, Agata& Kapłon-Cieślicka, Agnieszka& Ozierański, Krzysztof& Budnik, Monika& Wancerz, Anna& Sypień, Piotr…[et al.]. 2019. Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction. Disease Markers،Vol. 2019, no. 2019, pp.1-12.
https://search.emarefa.net/detail/BIM-1148034
Modern Language Association (MLA)
Tymińska, Agata…[et al.]. Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction. Disease Markers No. 2019 (2019), pp.1-12.
https://search.emarefa.net/detail/BIM-1148034
American Medical Association (AMA)
Tymińska, Agata& Kapłon-Cieślicka, Agnieszka& Ozierański, Krzysztof& Budnik, Monika& Wancerz, Anna& Sypień, Piotr…[et al.]. Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction. Disease Markers. 2019. Vol. 2019, no. 2019, pp.1-12.
https://search.emarefa.net/detail/BIM-1148034
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1148034